AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06364527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Digital Health respiratory disease management platform
Description: The Aptar Digital Health respiratory disease management platform is a digital health tool that combines a Healthcare Professional portal (BreatheSmart Connect) and an associated patient mobile application (BreatheSmart mobile application). The Aptar Digital Health respiratory disease management platform is intended to be used in conjunction with compatible connected sensor devices that track medication adherence and for some, technique.
Study NCT05548894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilization splint
Description: upper acrylic splint rest on the maxillary teeth and had flat surface
Study NCT05548894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy
Description: The laser apparatus had a hand piece on which either a specially designed optic prism was attached to transfer laser energy to the tip of the prism
Study NCT05548894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilization splint and laser therapy
Description: the stabilization splint used in combination of treatment with laser therapy
Study NCT02516436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Buprenorphine NX
Description: Buprenorphine with naloxone
Study NCT02516436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine
Study NCT05602896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sepsis education
Description: The education program has been reviewed and approved by BJH Center for Practice Excellence
Study NCT05874570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT05874570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT05874570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT05874570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT05874570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Antibiotics for H. pylori eradication
Study NCT05874570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Antibiotics for H. pylori eradication
Study NCT05874570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Antibiotics for H. pylori eradication
Study NCT05874570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Antibiotics for H. pylori eradication
Study NCT04829578 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypnosis
Description: Chronic idiopathic pruritus is treated by hypnosis
Study NCT05883826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual health training
Description: The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
Study NCT05373238 — intervention group
Intervention type: PROCEDURE
Intervention: Early discharge
Description: Early discharge
Study NCT04430907 — intervention group
Intervention type: BIOLOGICAL
Intervention: HPV 9-valent Vaccine, Recombinant
Description: After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey.
Study NCT04881838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P regimen
Description: Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
Study NCT04881838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course A1 + Vin
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
Study NCT04881838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course B1 +Vin
Description: vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
Study NCT04881838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course A2 + Vin
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
Study NCT04881838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course B2 +Vin
Description: vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
Study NCT05699681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic and transesophageal echocardiography
Description: After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~* Apical four chamber (A4C) view~* Apical two chamber view (A2C) view~* Right ventricle (RV) focused A4C view~* Right ventricular systolic pressure (RVSP)~* Pulmonary arterial acceleration time (PAAT),~* Tricuspid annular plane systolic excursion (TAPSE),~* Tricuspid annular plane systolic velocity (s'),~* Right ventricular fractional area change (RV FAC)~* RV free wall strain,~* RV myocardial performance index (MPI),~* RV isovolumic relaxation time (IVRT),~* RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon.
Study NCT04881838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course A3 + Vin
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
Study NCT04881838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course B3 +Vin
Description: vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
Study NCT04881838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Description: Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
Study NCT05154968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride
Description: Administered SC infusion.
Study NCT05154968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate buffer
Description: Administered SC infusion.
Study NCT05154968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Administered SC infusion.
Study NCT05154968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Autoinjector
Description: Used to administer the drug through SC infusion.
Study NCT06086262 — intervention group
Intervention type: DEVICE
Intervention: Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)
Description: The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force.
Study NCT05595759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Violence against women education supported by creative drama
Description: Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
Study NCT05595759 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine service operation
Description: No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.
Study NCT05398081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime (Zinnat®)
Description: Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
Study NCT05398081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone (Rocephin®)
Description: Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
Study NCT06213675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation treatment
Description: Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.
Study NCT06213675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation treatment
Description: Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.
Study NCT06213675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Injection
Description: The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
Study NCT06506071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spectral CT
Description: Myocardial tissue characterization with Spectral CT
Study NCT05193227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-01
Description: Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
Study NCT05193227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)
Description: Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
Study NCT06370078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin Human
Description: To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
Study NCT06370078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Human
Description: To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
Study NCT06436300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational text messaging
Description: Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.
Study NCT04673058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.
Study NCT04673058 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.
Study NCT05595876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent retriever thrombectomy
Description: The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
Study NCT05595876 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: contact aspiration thrombectomy
Description: A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
Study NCT05516329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide
Description: The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.
Study NCT05241652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training with an intensity of 50% MIP
Description: Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
Study NCT05241652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inspiratory Muscle Training with an intensity of 10% MIP
Description: Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
Study NCT06503198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual care
Description: Through Cloud DX, intervention group participants will receive:~Remote Automated Monitoring: measurement of: blood pressure, heart rate, respiratory rate, oxygen saturation, temperature and weight.~Frailty-tailored daily symptom survey: The recovery survey consists of questions related to infection, bleeding, pain, appetite, dehydration, appetite, syncope and falls.~The tablet will prompt the participant to complete a Katz Index of Independence in Activities of Daily Living (IADL) survey. The FAM-CAM survey will also be pushed by Cloud DX to be completed.~Virtual RN assessment: a virtual RN assessment will be scheduled at a minimum of every 2 days for the first 7 days. The virtual RN will also perform the 4AT Delirium Assessment.~Medications: the virtual RN will undertake medication review and reconciliation. In addition, they will provide counselling regarding analgesic support and monitor for drug interactions.
Study NCT04888611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus GSC-DCV
Description: Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
Study NCT04888611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab plus Placebo
Description: Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
Study NCT04800380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Edpuzzle interactive videos
Description: The effectiveness of the Edpuzzle application will be evaluated in developing the metric and drug dose calculation skills of first year nursing students.
Study NCT03973814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermax Blood Warmer
Description: Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
Study NCT05437887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fucoidan
Description: All patients consumed fucoidan.
Study NCT04733820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Study NCT06041555 — intervention group
Intervention type: OTHER
Intervention: 3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed
Description: Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
Study NCT05134909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized contact lens
Description: The customized lenses are designed to correct the eye's optical aberrations.
Study NCT05152212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVGN7409
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Study NCT04638452 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video & movements recording
Description: Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
Study NCT04638452 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Passing self and hetero questionnaires of emotion felt and perceived.
Study NCT03850795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-1119
Description: oral once daily 80 mg
Study NCT03850795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: oral once daily 160 mg
Study NCT06451575 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection
Study NCT05015660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing lead (Select Secure 3830 lead)
Description: Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
Study NCT05015660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular active fixation lead
Description: Active fixation lead (standard)
Study NCT04543357 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Samples for NAb and ADA to AAV9
Study NCT05327608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-Term Fasting
Description: Undergo intermittent fasting
Study NCT05516056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS clinical pathway
Description: Prospective evaluation of the clinical results of ERAS implementation in the first 50 patients undergoing ERAS for cholecystectomy in CHUK, Rwanda
Study NCT03763396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KCZ)
Description: Oral Tablet
Study NCT03763396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole (PCZ)
Description: Delayed Release Oral Tablet
Study NCT05238961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714
Description: Investigational PET Tracer \[18F\]DPA-714
Study NCT03609866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid thoracic compression technique
Description: in the expiratory time of the ventilation set, it will be applied a rapid thoracic compression